Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.

PMID:
31157962
2.

Targeted mutation detection in breast cancer using MammaSeq™.

Smith NG, Gyanchandani R, Shah OS, Gurda GT, Lucas PC, Hartmaier RJ, Brufsky AM, Puhalla S, Bahreini A, Kota K, Wald AI, Nikiforov YE, Nikiforova MN, Oesterreich S, Lee AV.

Breast Cancer Res. 2019 Feb 8;21(1):22. doi: 10.1186/s13058-019-1102-7.

3.

Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy.

Han M, Salamat A, Zhu L, Zhang H, Clark BZ, Dabbs DJ, Carter GJ, Brufsky AM, Jankowitz RC, Puhalla SL, Johnson RR, Soran A, Steiman JG, McAuliffe PF, Diego EJ, Bhargava R.

Mod Pathol. 2019 Jun;32(6):807-816. doi: 10.1038/s41379-019-0208-x. Epub 2019 Feb 5.

PMID:
30723293
4.

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.

Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL 3rd, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N.

Lancet Oncol. 2019 Jan;20(1):88-99. doi: 10.1016/S1470-2045(18)30621-1. Epub 2018 Nov 30. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30509771
5.

Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood.

Gyanchandani R, Kvam E, Heller R, Finehout E, Smith N, Kota K, Nelson JR, Griffin W, Puhalla S, Brufsky AM, Davidson NE, Lee AV.

Sci Rep. 2018 Nov 23;8(1):17313. doi: 10.1038/s41598-018-35470-9.

6.

Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use.

Pandey A, Brufsky AM.

Clin Breast Cancer. 2019 Feb;19(1):e7-e11. doi: 10.1016/j.clbc.2018.09.010. Epub 2018 Oct 4. No abstract available.

PMID:
30391215
7.

Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues.

Heng YJ, Wang J, Ahearn TU, Brown SB, Zhang X, Ambrosone CB, de Andrade VP, Brufsky AM, Couch FJ, King TA, Modugno F, Vachon CM, DuPre NC, Garcia-Closas M, Troester MA, Hunter DJ, Eliassen AH, Tamimi RM, Hankinson SE, Beck AH.

Breast Cancer Res Treat. 2019 Feb;173(3):667-677. doi: 10.1007/s10549-018-5034-1. Epub 2018 Nov 1.

PMID:
30387004
8.

Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.

Basudan A, Priedigkeit N, Hartmaier RJ, Sokol ES, Bahreini A, Watters RJ, Boisen MM, Bhargava R, Weiss KR, Karsten MM, Denkert C, Blohmer JU, Leone JP, Hamilton RL, Brufsky AM, Elishaev E, Lucas PC, Lee AV, Oesterreich S.

Mol Cancer Res. 2019 Feb;17(2):457-468. doi: 10.1158/1541-7786.MCR-18-0946. Epub 2018 Oct 24.

PMID:
30355675
9.

Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer.

Merriman JD, Sereika SM, Conley YP, Koleck TA, Zhu Y, Phillips ML, Bertocci MA, Brufsky AM, Bender CM.

Biol Res Nurs. 2019 Jan;21(1):50-60. doi: 10.1177/1099800418799964. Epub 2018 Sep 13.

PMID:
30213196
10.

Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.

Stearns V, Brufsky AM, Verma S, Cotter MJ, Lu DR, Dequen F, Joy AA.

Clin Breast Cancer. 2018 Dec;18(6):e1239-e1245. doi: 10.1016/j.clbc.2018.07.007. Epub 2018 Jul 30.

PMID:
30172722
11.

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).

Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr.

J Clin Oncol. 2018 Sep 1;36(25):2621-2629. doi: 10.1200/JCO.2018.79.2028. Epub 2018 Jul 24.

PMID:
30040523
12.

Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.

Varešlija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, O'Halloran PJ, Ward E, Cocchiglia S, Hartmaier R, Castro CA, Zhu L, Tseng GC, Lucas PC, Puhalla SL, Brufsky AM, Hamilton RL, Mathew A, Leone JP, Basudan A, Hudson L, Dwyer R, Das S, O'Connor DP, Buckley PG, Farrell M, Hill ADK, Oesterreich S, Lee AV, Young LS.

J Natl Cancer Inst. 2019 Apr 1;111(4):388-398. doi: 10.1093/jnci/djy110.

13.

Pathologist's health-care value in the triage of Oncotype DX® testing: a value-based pathology study of tumour biology with outcomes.

Dabbs DJ, Clark BZ, Serdy K, Onisko A, Brufsky AM, Smalley S, Perkins S, Bhargava R.

Histopathology. 2018 Oct;73(4):692-700. doi: 10.1111/his.13690. Epub 2018 Aug 6.

PMID:
29920746
14.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

15.

Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?

Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R.

Am J Clin Pathol. 2018 May 31;150(1):34-42. doi: 10.1093/ajcp/aqy028.

PMID:
29741562
16.

Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer.

Bender CM, Merriman JD, Sereika SM, Gentry AL, Casillo FE, Koleck TA, Rosenzweig MQ, Brufsky AM, McAuliffe P, Zhu Y, Conley YP.

Oncol Nurs Forum. 2018 May 1;45(3):308-326. doi: 10.1188/18.ONF.308-326.

17.

Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer.

Clark BZ, Farrugia DJ, Landmann A, Diego EJ, Dabbs DJ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R.

Am J Clin Pathol. 2018 Mar 7;149(4):332-343. doi: 10.1093/ajcp/aqx168.

PMID:
29481634
18.

Effect of gastroretentive gabapentin (Gralise) on postmastectomy pain syndrome: a proof-of-principle open-label study.

Belfer I, Pollock NI, Martin JL, Lim KG, De La Cruz C, Van Londen G, Nunziato-Virga SR, Stranieri K, Brufsky AM, Wang H.

Pain Rep. 2017 Apr 11;2(3):e596. doi: 10.1097/PR9.0000000000000596. eCollection 2017 May.

19.

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali SM, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL, Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, Brufsky AM, Frampton GM, Stephens PJ, Chmielecki J, Lee AV.

Ann Oncol. 2018 Apr 1;29(4):872-880. doi: 10.1093/annonc/mdy025.

20.

Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.

Brufsky AM, Dickler MN.

Oncologist. 2018 May;23(5):528-539. doi: 10.1634/theoncologist.2017-0423. Epub 2018 Jan 19. Review.

21.

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.

Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL 3rd, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N.

J Clin Oncol. 2017 Dec 10;35(35):3942-3948. doi: 10.1200/JCO.2017.74.1165. Epub 2017 Oct 26.

22.

Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.

Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx162.

23.

Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases.

Priedigkeit N, Watters RJ, Lucas PC, Basudan A, Bhargava R, Horne W, Kolls JK, Fang Z, Rosenzweig MQ, Brufsky AM, Weiss KR, Oesterreich S, Lee AV.

JCI Insight. 2017 Sep 7;2(17). pii: 95703. doi: 10.1172/jci.insight.95703. eCollection 2017 Sep 7.

24.

Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer.

Mathew A, Achkar T, Abberbock S, Sandhu GS, Jacob ME, Villgran VD, Rosenzweig MQ, Puhalla S, Brufsky AM.

Breast J. 2017 Nov;23(6):718-722. doi: 10.1111/tbj.12905. Epub 2017 Aug 28.

25.
26.

Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.

Farrugia DJ, Landmann A, Zhu L, Diego EJ, Johnson RR, Bonaventura M, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Lembersky BC, Ahrendt GM, McAuliffe PF, Bhargava R.

Mod Pathol. 2017 Aug;30(8):1078-1085. doi: 10.1038/modpathol.2017.41. Epub 2017 May 26.

27.

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N.

J Clin Oncol. 2017 Aug 10;35(23):2647-2655. doi: 10.1200/JCO.2016.71.4147. Epub 2017 Apr 11.

28.

Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer.

Yee MK, Sereika SM, Bender CM, Brufsky AM, Connolly MC, Rosenzweig MQ.

Cancer. 2017 Jun 1;123(11):2061-2069. doi: 10.1002/cncr.30575. Epub 2017 Feb 15.

29.

Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer.

Koleck TA, Bender CM, Sereika SM, Ryan CM, Ghotkar P, Brufsky AM, Jankowitz RC, McAuliffe PF, Clark BZ, Conley YP.

Cancer Med. 2017 Feb;6(2):339-348. doi: 10.1002/cam4.964. Epub 2017 Jan 13.

30.
31.

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.

Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Puhalla SL, Davidson NE, Oesterreich S, Brufsky AM, Young L, Lee AV.

JAMA Oncol. 2017 May 1;3(5):666-671. doi: 10.1001/jamaoncol.2016.5630. Erratum in: JAMA Oncol. 2017 Mar 1;3(3):418.

32.

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Zoon CK, Kidwell KM, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N.

Ann Surg Oncol. 2017 Jul;24(7):1853-1860. doi: 10.1245/s10434-016-5662-9. Epub 2016 Nov 18.

33.

Understanding the Needs of Patients with Metastatic Breast Cancer: Results of the Make Your Dialogue Count Survey.

Brufsky AM, Ormerod C, Bell Dickson R, Citron ML.

Breast J. 2017 Jan;23(1):17-25. doi: 10.1111/tbj.12675. Epub 2016 Sep 13.

PMID:
27623209
34.

Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.

Gyanchandani R, Kota KJ, Jonnalagadda AR, Minteer T, Knapick BA, Oesterreich S, Brufsky AM, Lee AV, Puhalla SL.

Oncotarget. 2016 Aug 19;8(40):66901-66911. doi: 10.18632/oncotarget.11383. eCollection 2017 Sep 15.

35.

Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?

Brufsky AM, Davidson NE.

Clin Cancer Res. 2016 Oct 15;22(20):4963-4965. Epub 2016 Aug 12.

36.

Pathways Clinical Decision Support for Appropriate Use of Key Biomarkers.

Ellis PG, Brufsky AM, Beriwal S, Lokay KG, Benson HO, McCutcheon SB, Krebs M.

J Oncol Pract. 2016 Jun;12(6):e681-7. doi: 10.1200/JOP.2015.010546. Epub 2016 May 24.

PMID:
27221995
37.

Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory study.

Koleck TA, Bender CM, Sereika SM, Brufsky AM, Lembersky BC, McAuliffe PF, Puhalla SL, Rastogi P, Conley YP.

Springerplus. 2016 Apr 9;5:422. doi: 10.1186/s40064-016-2061-4. eCollection 2016.

38.

Beliefs in Chemotherapy and Knowledge of Cancer and Treatment Among African American Women With Newly Diagnosed Breast Cancer.

Jiang Y, Sereika SM, Bender CM, Brufsky AM, Rosenzweig MQ.

Oncol Nurs Forum. 2016 Mar;43(2):180-9. doi: 10.1188/16.ONF.180-189.

PMID:
26906129
39.

Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer.

Gurda GT, Ambros T, Nikiforova MN, Nikiforov YE, Lucas PC, Dabbs DJ, Lee AV, Brufsky AM, Puhalla SL, Bhargava R.

Appl Immunohistochem Mol Morphol. 2017 Jul;25(6):392-398. doi: 10.1097/PAI.0000000000000322.

PMID:
26862949
40.

Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

Brufsky AM.

Clin Med Insights Oncol. 2015 Dec 30;9:137-47. doi: 10.4137/CMO.S31586. eCollection 2015. Review.

41.

Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.

Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N.

Lancet. 2016 Feb 27;387(10021):857-65. doi: 10.1016/S0140-6736(15)01169-1. Epub 2015 Dec 11.

42.

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.

Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N.

Lancet. 2016 Feb 27;387(10021):849-56. doi: 10.1016/S0140-6736(15)01168-X. Epub 2015 Dec 11.

43.

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.

Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, Kurland BF, Weiss KR, Mathew A, Leone JP, Davidson NE, Nikiforova MN, Brufsky AM, Ambros TF, Stern AM, Puhalla SL, Lee AV, Oesterreich S.

Clin Cancer Res. 2016 Mar 1;22(5):1130-7. doi: 10.1158/1078-0432.CCR-15-1534. Epub 2015 Oct 23.

44.

Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer.

Merriman JD, Sereika SM, Brufsky AM, McAuliffe PF, McGuire KP, Myers JS, Phillips ML, Ryan CM, Gentry AL, Jones LD, Bender CM.

Psychooncology. 2017 Jan;26(1):44-52. doi: 10.1002/pon.4009. Epub 2015 Oct 20.

45.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.

N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

46.

Developing in vitro models of human ductal carcinoma in situ from primary tissue explants.

Brown DD, Dabbs DJ, Lee AV, McGuire KP, Ahrendt GM, Bhargava R, Davidson NE, Brufsky AM, Johnson RR, Oesterreich S, McAuliffe PF.

Breast Cancer Res Treat. 2015 Sep;153(2):311-21. doi: 10.1007/s10549-015-3551-8. Epub 2015 Aug 18.

PMID:
26283301
47.

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N.

Lancet Oncol. 2015 Sep;16(9):1037-1048. doi: 10.1016/S1470-2045(15)00041-8. Epub 2015 Aug 10. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589.

48.

Some Excitement, Some Disappointment.

Brufsky AM.

Oncology (Williston Park). 2015 Jul;29(7):494-5. No abstract available.

49.

Expression of high affinity folate receptor in breast cancer brain metastasis.

Leone JP, Bhargava R, Theisen BK, Hamilton RL, Lee AV, Brufsky AM.

Oncotarget. 2015 Oct 6;6(30):30327-33. doi: 10.18632/oncotarget.4639.

50.

Patterns of change in cognitive function with anastrozole therapy.

Bender CM, Merriman JD, Gentry AL, Ahrendt GM, Berga SL, Brufsky AM, Casillo FE, Dailey MM, Erickson KI, Kratofil FM, McAuliffe PF, Rosenzweig MQ, Ryan CM, Sereika SM.

Cancer. 2015 Aug 1;121(15):2627-36. doi: 10.1002/cncr.29393. Epub 2015 Apr 23.

Supplemental Content

Loading ...
Support Center